<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44-vaccines-08-00142">
 <label>44.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Marzi</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Engelmann</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Feldmann</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Haberthur</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Shupert</surname>
    <given-names>W.L.</given-names>
   </name>
   <name>
    <surname>Brining</surname>
    <given-names>U.</given-names>
   </name>
   <name>
    <surname>Scott</surname>
    <given-names>D.P.</given-names>
   </name>
   <name>
    <surname>Geisbert</surname>
    <given-names>T.W.</given-names>
   </name>
   <name>
    <surname>Kawaoka</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Katze</surname>
    <given-names>M.G.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Antibodies are necessary for rVSV/ZEBOV-GPâ€“mediated protection against lethal Ebola virus challenge in nonhuman primates</article-title>
  <source>Proc. Natl. Acad. Sci. USA</source>
  <year>2013</year>
  <volume>110</volume>
  <fpage>1893</fpage>
  <lpage>1898</lpage>
  <pub-id pub-id-type="doi">10.1073/pnas.1209591110</pub-id>
  <pub-id pub-id-type="pmid">23319647</pub-id>
 </element-citation>
</ref>
